Inspire Medical Systems (INSP) stock plummeted on Tuesday following the release of the medical technology company’s Q2 2025 earnings report. This started with adjusted earnings per share of 45 cents, compared to Wall Street’s estimate of 20 cents. The company’s adjusted EPS also increased 40.63% year-over-year from 32 cents.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Inspire Medical Systems reported revenue of $217.1 million in Q2, which surpassed analysts’ estimate of $214.49 million. It was also up 11% from the $195.88 million reported in the second quarter of 2024. This was fueled by the launch of its Inspire V system in the U.S.
However, investors’ hopes were hurt when Inspire Medical Systems Chairman and CEO Tim Herbert noted that “the U.S. commercial launch is progressing slower than expected, and the timeline to complete the full transition to Inspire V has been pushed forward, which will impact financial results for the year.”
Inspire Medical Systems Guidance
Inspire Medical Systems lowered its 2025 guidance in its latest earnings report. It now expects revenue for the year to range from $900 million to $910 million, compared to its previous estimate of $940 to $955 million. This would also see it miss Wall Street’s 2025 revenue estimate of $914.74 million.
Inspire Medical Systems stock was down 30.48% in pre-market trading on Tuesday, following a 3.05% rally yesterday. The shares have also decreased 29.9% year-to-date and 11.6% over the past 12 months.
The guidance cut announced by Inspire Medical Systems has already resulted in several lowered price targets, including UBS analyst Danielle Antalffy cutting her price target for INSP shares to $230 from $270.
Is Inspire Medical Systems Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts’ consensus rating for Inspire Medical Systems is Strong Buy, based on 10 Buy and three Hold ratings over the past 12 months. With that comes an average INSP stock price target of $210.09, representing a potential 61.67% upside for the shares. These ratings and price targets will likely change as analysts update their coverage after today’s earnings report.
